5-ethyl-2-furfuryldimethylamine | 75523-44-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-ethyl-2-furfuryldimethylamine
• 英文别名: 1-(5-ethylfuran-2-yl)-N,N-dimethylmethanamine
• CAS: 75523-44-3
• 化学式: C₉H₁₅NO
• 分子量: 153.224
• InChiKey: UQJSVLTXANZVPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-ethyl-2-furfuryldimethylamine 、 碘甲烷 以 乙醇 为溶剂， 生成 5-ethyl-2-furfuryltrimethylammonium iodide
  参考文献：
  名称：

  Pratesi; Villa; Ferri, Farmaco, Edizione Scientifica, 1980, vol. 35, # 8, p. 621 - 635

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基呋喃 、 聚合甲醛 、 二甲胺 在 溶剂黄146 作用下， 反应 3.0h， 生成 5-ethyl-2-furfuryldimethylamine
  参考文献：
  名称：

  Cholinergic agents structurally related to furtrethonium. 1

  摘要：

  A series of 5-substituted-2-(dimethylaminomethyl)-furyl derivatives 4 was prepared, with the aim of discovering novel antimuscarinic agents which are selective for smooth muscle as opposed to cardiac tissue. Both non-quaternary and quaternary ammonium compounds were synthesised. The agonist starting point, furtrethonium 3, was gradually transformed into antagonist by introduction of lipophilic and bulky groups in position 5 of this molecule. In particular, the introduction of alpha-hydroxy-alpha-cyclohexylbenzyl moiety (compound 9b), a lipophilic group characteristic of antimuscarinic agents, caused an appreciable increase of the antagonist's potency, and the lengthening of the distance between this lipophilic group and the furan ring, obtained by introduction of an ester, ether or amide group, led to some selectivity towards smooth muscle (compounds 19, 21, 25). Interestingly, compound 19, with an ester moiety as a spacer group, proved to be at least 20 times more potent in rat ileum (pK(B) = 7.3) and rat bladder (pK(B) = 7.2) than guinea-pig atria (pK(B) = 5.9).

  DOI：

  10.1016/0223-5234(94)90213-5

文献信息

• [EN] CARBONYL DERIVATIVES OF BETULIN<br/>[FR] DÉRIVÉS CARBONYLES DE BÉTULINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013020245A1

  公开（公告）日：2013-02-14

  Disclosed are a compound characterized by the following formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, wherein R3, L, and A are as described in the application. Said compounds are useful for the treatment of HIV.

  揭示了一种由以下化学式I或其药学上可接受的盐所表征的化合物，以及包含所述化合物或其药学上可接受的盐的药物组合物，其中R3、L和A如申请中所述。所述化合物对治疗HIV有用。
• 8-Hydroxyquinoline compounds and methods thereof
  申请人：Bursavich Matthew G.

  公开号：US20080269213A1

  公开（公告）日：2008-10-30

  The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.

  本发明涉及8-羟基喹啉化合物；包含一种8-羟基喹啉化合物的组合物；以及治疗或预防金属蛋白酶相关疾病的方法，例如关节炎、骨关节炎、恶性肿瘤、类风湿性关节炎、哮喘、慢性阻塞性肺病、动脉粥样硬化、年龄相关性黄斑变性、心肌梗死、角膜溃疡、眼表疾病、肝炎、主动脉瘤、肌腱炎、中枢神经系统疾病、异常伤口愈合、血管生成、再狭窄、肝硬化、多发性硬化症、肾小球肾炎、移植物抗宿主病、糖尿病、炎性肠病、休克、椎间盘退化、中风、骨质疏松或牙周疾病；或者包括向需要的哺乳动物施用有效剂量的8-羟基喹啉化合物。
• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。
• STUDIES ON THE STRUCTURE-ACTION RELATIONSHIPS OF PARASYMPATHOMIMETIC FURAN COMPOUNDS
  作者：A. K. ARMITAGE、H. R. ING

  DOI：10.1111/j.1476-5381.1954.tb01696.x

  日期：1954.9
• US7449447B2
  申请人：——

  公开号：US7449447B2

  公开（公告）日：2008-11-11